Literature DB >> 2574069

The course of tardive dyskinesia in patients on long-term neuroleptics.

J A Bergen1, E A Eyland, J A Campbell, P Jenkings, K Kellehear, A Richards, P J Beumont.   

Abstract

Results are presented of five consecutive annual examinations using the Abnormal Involuntary Movement Scale for 101 community-based chronic psychiatric patients. These 101 patients had a history of longer and more consistent neuroleptic treatment than the 231 patients who initially entered the study, so no conclusions about prevalence of TD can be drawn. At each examination two-thirds of this group showed signs of TD; however, only 45% were TD positive at most examinations and 24% were best described as having fluctuating TD status. Of those patients who were consistently TD positive, 82% showed no overall significant change in summed AIMS scores, 11% improved and 7% became worse.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574069     DOI: 10.1192/bjp.154.4.523

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  10 in total

1.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose.

Authors:  M F Egan; T M Hyde; J E Kleinman; R J Wyatt
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

Review 3.  Benzodiazepines for antipsychotic-induced tardive dyskinesia.

Authors:  Hanna Bergman; Paranthaman S Bhoopathi; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-01-20

Review 4.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

Review 5.  Anticholinergic medication for antipsychotic-induced tardive dyskinesia.

Authors:  Hanna Bergman; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-01-17

Review 6.  Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.

Authors:  Karla Soares-Weiser; John Rathbone; Yusuke Ogawa; Kiyomi Shinohara; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19

Review 7.  Cholinergic medication for antipsychotic-induced tardive dyskinesia.

Authors:  Irina Tammenmaa-Aho; Rosie Asher; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19

Review 8.  Vitamin E for antipsychotic-induced tardive dyskinesia.

Authors:  Karla Soares-Weiser; Nicola Maayan; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-01-17

Review 9.  Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.

Authors:  Hany G El-Sayeh; John Rathbone; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-01-18

10.  Reversibility of tardive dyskinesia syndrome.

Authors:  Angel Vinuela; Un Jung Kang
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-11-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.